MiNA Therapeutics

MiNA Therapeutics: Versatile, proprietary small activating ribonucleic acid (saRNA) therapeutics platform, analogous to RNAi opportunity, with rapid internal pipeline buildout initially focusing on oncology and genetic rare diseases enabled by current delivery technology (from BioNTech). Clinical proof of concept achieved in 2020 for first saRNA, orphan designation with current study aimed at potential accelerated approval in 2024. Advancing 10 different saRNA assets (some in multiple indications) into the clinic by 2025. Randomized Ph2 study for lead RNAa drug candidate MTL-CEBPA combined with sorafenib in second line hepatocellular carcinoma launched January 2022. Ph1b readout in solid tumors (MTL-CEBPA+Pembro PD-1) in 1Q22. Raised $30M Series A lead by aMoon (Sep 2020). $1.5B+ partnerships with Eli Lilly, Servier, AstraZeneca; $25M upfront from recent Lilly deal.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Oncology, Rare Disease
Investment Participation
Series A
Listing
Private
Market Cap
Private
Therapeutic Modalities
Platform Technology
Website:
Profiles:
Address:
84 Wood Lane
London, England W12 0BZ
United Kingdom

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • Robert Habib, Chief Executive Officer
  • Robin Wright, CFO